|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bowtell DD: The genesis and evolution of
high-grade serous ovarian cancer. Nat Rev Cancer. 10:803–808. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Feigenberg T, Clarke B, Virtanen C,
Plotkin A, Letarte M, Rosen B, Bernardini MQ, Kollara A, Brown TJ
and Murphy KJ: Molecular profiling and clinical outcome of
high-grade serous ovarian cancer presenting with low- versus
high-volume ascites. Biomed Res Int. 2014:3671032014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lengyel E: Ovarian cancer development and
metastasis. Am J Pathol. 177:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rustin G, van der Burg M, Griffin C, Qian
W and Swart AM: Early versus delayed treatment of relapsed ovarian
cancer. Lancet. 377:380–381. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wilusz JE, Sunwoo H and Spector DL: Long
noncoding RNAs: Functional surprises from the RNA world. Genes Dev.
23:1494–1504. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nagano T and Fraser P: No-nonsense
functions for long noncoding RNAs. Cell. 145:178–181. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gupta RA, Shah N, Wang KC, Kim J, Horlings
HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, et al: Long
non-coding RNA HOTAIR reprograms chromatin state to promote cancer
metastasis. Nature. 464:1071–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gutschner T, Hämmerle M, Eissmann M, Hsu
J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, et al:
The noncoding RNA MALAT1 is a critical regulator of the metastasis
phenotype of lung cancer cells. Cancer Res. 73:1180–1189. 2013.
View Article : Google Scholar :
|
|
10
|
Yuan SX, Yang F, Yang Y, Tao QF, Zhang J,
Huang G, Yang Y, Wang RY, Yang S, Huo XS, et al: Long noncoding RNA
associated with microvascular invasion in hepatocellular carcinoma
promotes angiogenesis and serves as a predictor for hepatocellular
carcinoma patients’ poor recurrence-free survival after
hepatectomy. Hepatology. 56:2231–2241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
de Kok JB, Verhaegh GW, Roelofs RW,
Hessels D, Kiemeney LA, Aalders TW, Swinkels DW and Schalken JA:
DD3(PCA3), a very sensitive and specific marker to detect prostate
tumors. Cancer Res. 62:2695–2698. 2002.PubMed/NCBI
|
|
12
|
Sun M, Xia R, Jin F, Xu T, Liu Z, De W and
Liu X: Downregulated long noncoding RNA MEG3 is associated with
poor prognosis and promotes cell proliferation in gastric cancer.
Tumour Biol. 35:1065–1073. 2014. View Article : Google Scholar
|
|
13
|
Quagliata L, Matter MS, Piscuoglio S,
Arabi L, Ruiz C, Procino A, Kovac M, Moretti F, Makowska Z,
Boldanova T, et al: Long noncoding RNA HOTTIP/HOXA13 expression is
associated with disease progression and predicts outcome in
hepatocellular carcinoma patients. Hepatology. 59:911–923. 2014.
View Article : Google Scholar :
|
|
14
|
Ge X, Chen Y, Liao X, Liu D, Li F, Ruan H
and Jia W: Overexpression of long noncoding RNA PCAT-1 is a novel
biomarker of poor prognosis in patients with colorectal cancer. Med
Oncol. 30:5882013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang XS, Zhang Z, Wang HC, Cai JL, Xu QW,
Li MQ, Chen YC, Qian XP, Lu TJ, Yu LZ, et al: Rapid identification
of UCA1 as a very sensitive and specific unique marker for human
bladder carcinoma. Clin Cancer Res. 12:4851–4858. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tano K and Akimitsu N: Long non-coding
RNAs in cancer progression. Front Genet. 3:2192012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu W, Gius D, Onyango P, Muldoon-Jacobs K,
Karp J, Feinberg AP and Cui H: Epigenetic silencing of tumour
suppressor gene p15 by its antisense RNA. Nature. 451:202–206.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
El Messaoudi-Aubert S, Nicholls J,
Maertens GN, Brookes S, Bernstein E and Peters G: Role for the
MOV10 RNA helicase in polycomb-mediated repression of the INK4a
tumor suppressor. Nat Struct Mol Biol. 17:862–868. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pasmant E, Laurendeau I, Héron D, Vidaud
M, Vidaud D and Bièche I: Characterization of a germ-line deletion,
including the entire INK4/ARF locus, in a melanoma-neural system
tumor family: Identification of ANRIL, an antisense noncoding RNA
whose expression coclusters with ARF. Cancer Res. 67:3963–3969.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kotake Y, Nakagawa T, Kitagawa K, Suzuki
S, Liu N, Kitagawa M and Xiong Y: Long non-coding RNA ANRIL is
required for the PRC2 recruitment to and silencing of p15(INK4B)
tumor suppressor gene. Oncogene. 30:1956–1962. 2011. View Article : Google Scholar :
|
|
21
|
Yap KL, Li S, Muñoz-Cabello AM, Raguz S,
Zeng L, Mujtaba S, Gil J, Walsh MJ and Zhou MM: Molecular interplay
of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by
polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell.
38:662–674. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Turnbull C, Ahmed S, Morrison J, Pernet D,
Renwick A, Maranian M, Seal S, Ghoussaini M, Hines S, Healey CS, et
al: Breast Cancer Susceptibility Collaboration (UK): Genome-wide
association study identifies five new breast cancer susceptibility
loci. Nat Genet. 42:504–507. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen J, Li D, Wei C, Sen S, Killary AM,
Amos CI, Evans DB, Abbruzzese JL and Frazier ML: Aurora-A and p16
polymorphisms contribute to an earlier age at diagnosis of
pancreatic cancer in Caucasians. Clin Cancer Res. 13:3100–3104.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bei JX, Li Y, Jia WH, Feng BJ, Zhou G,
Chen LZ, Feng QS, Low HQ, Zhang H, He F, et al: A genome-wide
association study of nasopharyngeal carcinoma identifies three new
susceptibility loci. Nat Genet. 42:599–603. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stacey SN, Sulem P, Masson G, Gudjonsson
SA, Thorleifsson G, Jakobsdottir M, Sigurdsson A, Gudbjartsson DF,
Sigurgeirsson B, Benediktsdottir KR, et al: New common variants
affecting susceptibility to basal cell carcinoma. Nat Genet.
41:909–914. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rajaraman P, Melin BS, Wang Z,
McKean-Cowdin R, Michaud DS, Wang SS, Bondy M, Houlston R, Jenkins
RB, Wrensch M, et al: Genome-wide association study of glioma and
meta-analysis. Hum Genet. 131:1877–1888. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sherborne AL, Hosking FJ, Prasad RB, Kumar
R, Koehler R, Vijayakrishnan J, Papaemmanuil E, Bartram CR,
Stanulla M, Schrappe M, et al: Variation in CDKN2A at 9p21.3
influences childhood acute lymphoblastic leukemia risk. Nat Genet.
42:492–494. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu D, Wolf JK, Scanlon M, Price JE and
Hung MC: Enhanced c-erbB-2/neu expression in human ovarian cancer
cells correlates with more severe malignancy that can be suppressed
by E1A. Cancer Res. 53:891–898. 1993.PubMed/NCBI
|
|
29
|
Bai F, Feng J, Cheng Y, Shi J, Yang R and
Cui H: Analysis of gene expression patterns of ovarian cancer cell
lines with different metastatic potentials. Int J Gynecol Cancer.
16:202–209. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang Y, Dong L, Cui H, Shen DH, Wang Y,
Chang XH, Fu TY, Ye X and Yao YY: Up-regulation of mitochondrial
antioxidation signals in ovarian cancer cells with aggressive
biologic behavior. J Zhejiang Univ Sci B. 12:346–356. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shenhua X, Lijuan Q, Hanzhou N, Xinghao N,
Chihong Z, Gu Z, Weifang D and Yongliang G: Establishment of a
highly metastatic human ovarian cancer cell line (HO-8910PM) and
its characterization. J Exp Clin Cancer Res. 18:233–239.
1999.PubMed/NCBI
|
|
32
|
Panzitt K, Tschernatsch MM, Guelly C,
Moustafa T, Stradner M, Strohmaier HM, Buck CR, Denk H, Schroeder
R, Trauner M, et al: Characterization of HULC, a novel gene with
striking up-regulation in hepatocellular carcinoma, as noncoding
RNA. Gastroenterology. 132:330–342. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Du Y, Kong G, You X, Zhang S, Zhang T, Gao
Y, Ye L and Zhang X: Elevation of highly up-regulated in liver
cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell
proliferation via down-regulating p18. J Biol Chem.
287:26302–26311. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Congrains A, Kamide K, Oguro R, Yasuda O,
Miyata K, Yamamoto E, Kawai T, Kusunoki H, Yamamoto H, Takeya Y, et
al: Genetic variants at the 9p21 locus contribute to
atherosclerosis through modulation of ANRIL and CDKN2A/B.
Atherosclerosis. 220:449–455. 2012. View Article : Google Scholar
|
|
35
|
Sato K, Nakagawa H, Tajima A, Yoshida K
and Inoue I: ANRIL is implicated in the regulation of nucleus and
potential transcriptional target of E2F1. Oncol Rep. 24:701–707.
2010.PubMed/NCBI
|
|
36
|
Congrains A, Kamide K, Katsuya T, Yasuda
O, Oguro R, Yamamoto K, Ohishi M and Rakugi H: CVD-associated
non-coding RNA, ANRIL, modulates expression of atherogenic pathways
in VSMC. Biochem Biophys Res Commun. 419:612–616. 2012. View Article : Google Scholar : PubMed/NCBI
|
